Adam Kois

This inventor holds 21 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Texas Biotechnology Corporation, Signal Pharmaceuticals, Inc., Immunopharmaceutics, Inc.. Active years: 1995-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adam Kois. Retrieved from https://idiyas.com/inventor/adam-kois

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 1)

% Patents Active = 90.5

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 8.3

ph-index = 14

Forward Citations = 549(Granted Patents)

Location History:

Escondido, CA (US) (2003)
San Diego, CA (US) (1995 - 2012)

Company Filing History:

11 out of 37

Texas Biotechnology Corporation

patents

7 out of 169

Signal Pharmaceuticals, Inc.

patents

2 out of 3

Immunopharmaceutics, Inc.

patents

4. 1 out of 9

Encysive Pharmaceuticals, Inc.

patents

5. 1 out of 52

Pharmacopeia Drug Discovery, Inc.

patents

where one patent can have more than one assignee

Years Active: 1995-2012

Loading Chart...

Areas of Expertise:

Haloaryl Compounds

Anilinopyrimidine Derivatives

Endothelin Modulation

Estrogen Receptors

Sulfonamides

Biphenylsulfonamides

Aminopurines

Thienyl Derivatives

Furyl Compounds

Pyrrolyl-Sulfonamides

Phenyl Derivatives

Compositions

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8101588 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2012-01-24),

2. 7723340 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2010-05-25),

3. 7521446 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2009-04-21),

4. 7442699 - Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto (2008-10-28),

5. 7122544 - Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto (2006-10-17),

6. 6613804 - Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin (2003-09-02),

7. 6541498 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2003-04-01),

8. 6376523 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2002-04-23),

9. 6372739 - Compounds and methods for modulation of estrogen receptors (2002-04-16),

10. 6342610 - N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2002-01-29),

11. 6331637 - N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2001-12-18),

12. 6291456 - Compounds and methods for modulation of estrogen receptors (2001-09-18),

13. 6265428 - Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin (2001-07-24),

14. 6030991 - Benzenesulfonamides and the use thereof to modulate the activity of (2000-02-29),

15. 5977117 - Substituted phenyl compounds and derivatives thereof that modulate the (1999-11-02),

Title: Adam Kois: A Career Filled with Innovation and Success

Introduction:

Throughout his illustrious career, Adam Kois has continuously demonstrated his exceptional talent and passion for innovation. Hailing from San Diego, CA, Kois has made significant contributions to the field of biotechnology and pharmaceuticals. With an impressive portfolio of patents, Kois has been recognized for his groundbreaking work in developing novel treatments and compounds. This article delves into his latest patents, career highlights, influential collaborations, and the lasting impact of his inventions.

Latest Patents:

Adam Kois's latest patents revolve around his groundbreaking work on haloaryl substituted aminopurines, their compositions, and their applications in diverse treatment methods. These Aminopurine Compounds have demonstrated promising potential for therapeutic use, providing new avenues for combating various diseases and medical conditions. Kois's innovative approach has undoubtedly opened the door to further advancements in the medical field.

Career Highlights:

Over the course of his career, Adam Kois has accumulated an impressive patent portfolio, with a total of 21 patents to his name. Each patent showcases his ingenuity in developing innovative solutions to complex problems. Through his work, Kois has left an indelible mark on the biotechnology and pharmaceutical sectors, with his inventions poised to transform healthcare practices.

Collaborations:

Kois's remarkable achievements are not only a result of his individual brilliance but also of his collaborations with esteemed colleagues. Notably, he has worked with renowned companies such as Texas Biotechnology Corporation and Signal Pharmaceuticals, Inc. These collaborations have fostered an environment of collaboration and knowledge-sharing, enabling Kois to leverage his expertise and insights in partnership with industry leaders.

Among his coworkers, Ming Fai Chan and Vitukudi Narayanaiyengar Balaji have been indispensable contributors to Kois's research endeavors. Their collective efforts have enhanced the groundbreaking potential of Kois's inventions, further solidifying his position as an influential figure in the field.

Conclusion:

Adam Kois's remarkable career journey showcases his unwavering commitment to innovation and scientific excellence. With 21 patents and counting, his contributions have had a far-reaching impact on the biotechnology and pharmaceutical sectors. His latest patents centered around haloaryl substituted aminopurines demonstrate his ability to explore uncharted territory, revolutionizing treatment approaches for various diseases. Kois's collaborations and partnerships have also played a crucial role in bringing his inventions to fruition. Undoubtedly, Adam Kois's achievements will continue to inspire and shape the future of medical advancements.

Profile summary based on public USPTO records.